These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21836546)

  • 1. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 2. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
    Nandha R
    J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
    Salem M; Garcia JA
    Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
    J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
    Attard G; Reid AH; de Bono JS
    J Clin Oncol; 2010 Oct; 28(29):e560-1; author reply e562. PubMed ID: 20805462
    [No Abstract]   [Full Text] [Related]  

  • 7. Abiraterone in prostate cancer: a new angle to an old problem.
    Stein MN; Goodin S; Dipaola RS
    Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 9. Abiraterone and increased survival in metastatic prostate cancer.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
    [No Abstract]   [Full Text] [Related]  

  • 10. Abiraterone and castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
    [No Abstract]   [Full Text] [Related]  

  • 11. Changing therapeutic paradigms in castrate-resistant prostate cancer.
    Zivi A; Massard C; De-Bono J
    Clin Genitourin Cancer; 2010 Dec; 8(1):17-22. PubMed ID: 21208851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
    Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
    Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
    Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
    J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone and increased survival in metastatic prostate cancer.
    de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
    N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
    Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
    Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding treatment options for metastatic prostate cancer.
    Antonarakis ES; Eisenberger MA
    N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
    [No Abstract]   [Full Text] [Related]  

  • 19. First-line abiraterone improves survival in prostate cancer.
    Brower V
    Lancet Oncol; 2017 Jul; 18(7):e374. PubMed ID: 28602778
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
    Attard G; Belldegrun AS; de Bono JS
    BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.